Analysis of 111 cases of aristolochic acids nephropathy
10.12206/j.issn.2097-2024.202308066
- VernacularTitle:111例马兜铃酸肾病调查分析
- Author:
Wenhui SHI
1
;
Yanmei WANG
2
;
Li JIANG
1
;
Jun LI
1
;
Xiaomeng LI
1
;
Zhijun HE
1
Author Information
1. Beidaihe Rehabilitation and Recuperation Center of Joint Logistic Support Force, Qinhuangdao 066100, China.
2. NO.982 Hospital of Joint Logistic Support Force, Tangshan 066300, China.
- Keywords:
aristolochic acids;
aristolochic acid nephropathy;
interstitial nephritis;
Guanxinsuhe pill;
Longdanxiegan pill;
pharmacovigilance
- From:
Journal of Pharmaceutical Practice and Service
2024;42(1):38-42
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics and regularity of aristolochic acid nephropathy (AAN) induced by drugs containing aristolochic acid. Methods The clinical data of 111 patients with AAN induced by aristolochic acid were reviewed. The clinical features, medication and treatment of AAN were analyzed. Results Among 111 patients, there were more females than males (2.58∶1), 101 cases (90.99%) were over 50 years old； the mean age was (63.70±11.67) years old;the average duration of medication was (8.08±6.94) years. The drugs involved were Guanxinsuhe pill and Longdanxiegan pill in 106 cases (95.50%). Serum creatinine increased in 108 cases, urea nitrogen increased in 106 cases and hemoglobin decreased in 103 cases, most of which were hypogravity urine, mild to moderate proteinuria and occult blood. Ultrasonic examination revealed that the kidneys were damaged to varying degrees. Pathological biopsy of kidney showed renal tubular damage. Most patients had an insidious onset and varying degrees of progression, which were not proportional to the age and the duration of taking the medicine. In clinical, the renal function was progressively damaged, most of which were irreversible and with a poor prognosis. Conclusion Patients with renal impairment differed greatly individually, and the renal damage was not paralleled with the medication duration and dose of drugs containing aristolochic acid.AAN progressed rapidly, and the disease still progressed even after stopping taking drugs containing aristolochic acid. Strengthening pharmacovigilance, implementing early diagnosis and effective intervention could help to reduce the occurrence of AAN and attenuate its development.
